Thrombate III ® (antithrombin III [human]) Efficacy in Surgery
Protection during surgery
Antithrombin (AT) replacement helps prevent thromboembolism during surgery in patients with hereditary antithrombin deficiency1
a Not Thrombate III ® (antithrombin III [human]); plasma-derived antithrombin concentrate used was studied but not marketed. b Twenty-three patients underwent 57 operations of various types. Fourteen of the 23 patients had previous deep vein thrombosis. In 29 procedures, patients were not given thromboprophylaxis. In 28 procedures, thromboprophylaxis was used. c Also combined with other types of prophylaxis. d Dextran, low-dose heparin, peroral anticoagulants, and combinations. Adapted from Tengborn and Bergqvist.1
Thrombate III® (antithrombin III [human]) is indicated for the treatment of patients with hereditary antithrombin deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.
In clinical studies, the most common adverse events were dizziness, chest discomfort, nausea, and dysgeusia.
The anticoagulant effect of heparin is enhanced by concurrent treatment with Thrombate III in patients with hereditary AT-III deficiency. Thus, in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with Thrombate III.
Thrombate III is made from human plasma. Plasma products carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk. No cases of transmission of viral disease or CJD have ever been identified for Thrombate III.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.